Summary of Significant Accounting Policies - Additional Information (Detail)
|
3 Months Ended |
12 Months Ended |
|
|
Mar. 31, 2021
USD ($)
shares
|
Mar. 31, 2021
USD ($)
Number
shares
|
Mar. 31, 2020
USD ($)
Number
|
Mar. 31, 2019
USD ($)
Number
|
Mar. 31, 2018
USD ($)
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Concentration risk percentage |
|
100.00%
|
100.00%
|
100.00%
|
|
| Total restricted cash |
$ 8,400,000
|
$ 8,400,000
|
$ 8,400,000
|
|
|
| Inventory valuation reserves |
0
|
0
|
0
|
|
|
| Impairment losses of deferred cost of revenue |
|
0
|
1,300,000
|
$ 6,500,000
|
|
| Reduction of deferred cost of revenue |
|
|
400,000
|
2,200,000
|
|
| Customer refund liability |
|
|
900,000
|
4,300,000
|
|
| Internal-use software software, capitalized during the period |
|
4,000,000
|
6,000,000
|
500,000
|
|
| internal-use software Software, capitalized during the period |
|
500,000
|
700,000
|
0
|
|
| Impairment of long-lived assets |
|
0
|
33,213,000
|
0
|
|
| Breakage revenue from unreturned kits |
|
243,920,000
|
305,463,000
|
440,900,000
|
|
| Advertising costs |
|
$ 11,200,000
|
62,600,000
|
$ 136,800,000
|
|
| Deferred advertising costs |
|
|
$ 2,500,000
|
|
|
| Consumer Services [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Concentration risk percentage |
|
81.00%
|
89.00%
|
96.00%
|
|
| Breakage revenue from unreturned kits |
|
$ 197,525,000
|
$ 271,639,000
|
$ 425,534,000
|
|
| Deferred revenue |
39,300,000
|
39,300,000
|
38,800,000
|
74,100,000
|
$ 103,900,000
|
| Deferred revenue recognized |
|
$ 34,400,000
|
$ 59,900,000
|
$ 99,900,000
|
|
| Research Services [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Concentration risk percentage |
|
19.00%
|
9.00%
|
3.00%
|
|
| Breakage revenue from unreturned kits |
|
$ 46,341,000
|
$ 28,268,000
|
$ 12,385,000
|
|
| Deferred revenue |
31,900,000
|
31,900,000
|
48,600,000
|
48,700,000
|
$ 3,400,000
|
| Deferred revenue recognized |
|
42,800,000
|
28,700,000
|
1,900,000
|
|
| Deferred revenue related parties |
30,100,000
|
30,100,000
|
45,100,000
|
$ 0
|
|
| Deferred revenue recognized related parties |
|
39,900,000
|
26,700,000
|
|
|
| Transaction price allocated to remaining performance obligations |
$ 61,900,000
|
$ 61,900,000
|
108,300,000
|
|
|
| Research Services [Member] | Maximum [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Revenue, remaining performance obligation, expected timing of satisfaction, period |
|
|
|
3 years
|
|
| Research Services [Member] | Minimum [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Revenue, remaining performance obligation, expected timing of satisfaction, period |
1 year
|
1 year
|
|
|
|
| PGS Contracts [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Capitalized contract cost, net |
$ 3,300,000
|
$ 3,300,000
|
3,900,000
|
$ 9,900,000
|
|
| Capitalized contract cost, amortization period |
1 year
|
1 year
|
|
|
|
| Transferred over Time [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Breakage revenue from unreturned kits |
|
$ 24,100,000
|
38,000,000
|
57,000,000
|
|
| Consumer And Research Services [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Breakage revenue from unreturned kits |
|
243,866,000
|
299,907,000
|
437,919,000
|
|
| Therapeutics [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Breakage revenue from unreturned kits |
|
$ 54,000
|
$ 5,556,000
|
$ 2,981,000
|
|
| Series F-1 Redeemable Convertible Preferred Stock [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Temporary equity shares outstanding | shares |
17,291,066
|
17,291,066
|
|
|
|
| Fair value of preferred stock |
$ 272,700,000
|
$ 272,700,000
|
|
|
|
| Series F-1 Redeemable Convertible Preferred Stock [Member] | Consumer And Research Services [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Fair value measurement input |
16
|
16
|
|
|
|
| Series F-1 Redeemable Convertible Preferred Stock [Member] | Therapeutics [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Fair value measurement input |
20
|
20
|
|
|
|
| Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Fair value of the asset group |
$ 21,500,000
|
$ 21,500,000
|
|
|
|
| Supplier Concentration Risk [Member] | Cost Of Goods Microwaves [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Concentration risk percentage |
|
100.00%
|
100.00%
|
100.00%
|
|
| Supplier Concentration Risk [Member] | Cost Of Goods Kits [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Concentration risk percentage |
|
100.00%
|
100.00%
|
100.00%
|
|
| Supplier Concentration Risk [Member] | Cost Of Goods Processing Of Customer Samples [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Concentration risk percentage |
|
100.00%
|
100.00%
|
100.00%
|
|
| Supplier Concentration Risk [Member] | Cost Of Services Processing Of Customer Samples [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Number of major laboratory service provider | Number |
|
1
|
1
|
1
|
|
| Covid 19 [Member] |
|
|
|
|
|
| Summary Of Significant Accounting Policies [Line Items] |
|
|
|
|
|
| Impairment loss on operating lease right of use asset |
$ 12,600,000
|
|
|
|
|